I initiated my research career in the study of male infertility and the DAZ gene family. In this period, I performed RT-PCR, immunohistochemistry, and histological analysis. Afterwards, I worked at the Faculty of Pharmacy and Biochemistry of the University of Buenos Aires, in a preclinical study on intestinal inflammation and how stress affects the intestine. In parallel, I studied the extract of the Passiflora caerulea plant to test its effect in the intestine. To the techniques learned, I added Western Blot, HPLC, and PCR analysis. When I obtained my graduate, I decided to continue my training in Spain, in informatics. This is an essential field, which is constantly booming and helps to complement my previous knowledge. My final work investigated microRNAs (miRNAs) and their relationship with hepatocarcinoma, using text mining in R. Now I started my PhD. in Dr. Artero’s team, assuming this new challenge with great responsibility and enthusiasm: the study of new therapeutic targets using gapmers against Musashi 2 (MSI2). I hope to continue learning and contribute my bit to investigating Myotonic Dystrophy type I. 

I started in the Translational Genomics Group in 2018 as a collaborating student, and here I did my Final Degree and Master’s Projects and I have worked as a laboratory technician. I have also worked in different periods as a laboratory technician in ARTHEx Biotech, the Group’s spin-off, carrying out different research assistance tasks and combining this with my studies. In addition, in 2020 I obtained a Research Initiation Grant from the Information and Promotion Service (Sedi) of the Universitat de València to continue collaborating in the Group in continuity with my Final Degree Project. During these years, I have worked within the framework of Myotonic Dystrophy Type 1 and oligonucleotide-based therapies. Currently, I have just obtained an FPU fellowship (Training of University Teachers) from the Spanish Ministry of Universities to start my PhD with the aim of investigating pathogenesis mechanisms additional to Muscleblind proteins sequestration in Myotonic Dystrophy. 

I began my research career in the Pathophysiology and Therapies for Vision Diseases group at the CIPF, Valencia, where I gained experience in cell cultures and molecular biology techniques. Subsequently, I joined the Translational Genomics Group to undertake my master’s thesis, focusing on the characterization of the first murine model of type D2 girdle muscular dystrophy (LGMDD2), which provided me with expertise in techniques such as protein extraction, immunofluorescence, and immunohistochemistry. Currently, I am advancing the understanding of the molecular bases of LGMDD2 and exploring potential therapeutic drugs with the invaluable support of the Asociación Conquistando Escalones (ACE), which has been instrumental in facilitating my development as a researcher and the progress of this work. 

I began my research career as a biotechnologist, integrating my academic training with hands-on experience through internships and later as a laboratory technician in Ecuador. During this time, I developed a strong foundation in microbiology, biochemistry, molecular biology, and bioinformatics. I also gained practical expertise in key laboratory techniques, including antibiograms, nucleic acid extraction, PCR, sequencing, and bioinformatic analysis. Later, I decided to continue my academic training and recently completed the Master's in Research in Molecular, Cellular Biology, and Genetics at the Universitat de València in Spain. As part of this program, I had the opportunity to collaborate at the Príncipe Felipe Research Center, investigating markers of peripheral inflammation in the context of retinitis pigmentosa. For this study, we used murine and human cell cultures and applied techniques such as RNA extraction, RT-PCR, qPCR, Western Blot, and flow cytometry. I am currently pursuing my Ph.D. in Dr. Rubén Artero’s team, working on the project "Understanding TNPO3 Mutant-Induced Muscle Atrophy: Preclinical Models and Therapeutic Approaches in LGMDD2.

After completing my Bachelor studies in Biotechnology in the Polytechnic University of Valencia, which provided me with a strong background in molecular biology, genetic engineering, omics technologies, and bioinformatics tools, I decided to pursue a Master’s in Molecular Biomedicine at the University of Copenhagen to deepen my understanding of diseases at the molecular level. There, I had the opportunity to work on Huntington’s disease, studying the RNA-binding defect of RBM5 as a potential cause of neurodegeneration. This project strengthened my interest in RNA biology and RNA-based therapies, which recently led me to join the Human Translational Genomics Group as an MSCA PhD fellow within the ENTRY-DM doctoral network. My project focuses on investigating the contribution of miRNome alterations to DM1, beyond the classical Muscleblind sequestration model.

 LinkedIn

I hold a Master’s degree in Applied Biology to Biomedicine from the University of Pisa. My academic journey has always focused on genetics, from studying chromosomal aberrations to investigating a rare spinocerebellar ataxia (SCA27B) caused by a triplet repeat expansion in the FGF14 gene. Later, I worked as a research fellow in microbiology, focusing first on iatrogenic HPV transmission and then on an ERC-funded project optimizing bioinspired microrobots for automated and localized drug delivery. I am currently a Marie Curie pre-doctoral researcher in the Translational Genomics Group, contributing to the development of antisense oligonucleotide (ASO) therapies for myotonic dystrophy type 1 (DM1) within the ENTRY-DM project. I believe my multidisciplinary background will be valuable for advancing this project, with the hope of achieving tangible results that can positively impact patients’ lives

LinkedIn